{
    "Rank": 546,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT01344109",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "ECU 003"
                },
                "Organization": {
                    "OrgFullName": "Leo W. Jenkins Cancer Center",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "A Pilot Study of Tumor-Derived Exosomes as Diagnostic and Prognostic Markers in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy",
                "OfficialTitle": "A Pilot Study of Tumor-Derived Exosomes as Diagnostic and Prognostic Markers in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy"
            },
            "StatusModule": {
                "StatusVerifiedDate": "July 2017",
                "OverallStatus": "Withdrawn",
                "WhyStopped": "Lab company that was to do testing was sold",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "February 2011"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "December 2014",
                    "PrimaryCompletionDateType": "Anticipated"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "December 2014",
                    "CompletionDateType": "Anticipated"
                },
                "StudyFirstSubmitDate": "April 27, 2011",
                "StudyFirstSubmitQCDate": "April 27, 2011",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "April 28, 2011",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "July 18, 2017",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "July 21, 2017",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Susan E. Eubanks, RN, MSN, OCN",
                    "ResponsiblePartyInvestigatorTitle": "Clinical Trials Manager",
                    "ResponsiblePartyInvestigatorAffiliation": "Leo W. Jenkins Cancer Center"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Leo W. Jenkins Cancer Center",
                    "LeadSponsorClass": "OTHER"
                }
            },
            "OversightModule": {
                "OversightHasDMC": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "This is a pilot study evaluating the use of tumor derived exosomes as a marker for response to therapy in women receiving neoadjuvant chemotherapy for newly diagnosed breast cancer. Tumor derived exosome analysis may be a novel diagnostic and prognostic biosignature in breast cancer, which could prove to be a tool for earlier diagnosis, more effective treatments, and improved markers of response in order to increase survival rates."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Breast Neoplasms"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Observational",
                "DesignInfo": {
                    "DesignObservationalModelList": {
                        "DesignObservationalModel": [
                            "Case-Control"
                        ]
                    },
                    "DesignTimePerspectiveList": {
                        "DesignTimePerspective": [
                            "Prospective"
                        ]
                    }
                },
                "BioSpec": {
                    "BioSpecRetention": "Samples With DNA",
                    "BioSpecDescription": "Serum will be centrifuged to plasma which will be transferred to alliquots, and frozen prior to shipping. Exosomes will be extracted from the frozen plasma with half of the sample used for antibody testing and the remaining sample will be used for RNA analysis."
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "0",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Breast cancer patients",
                            "ArmGroupDescription": "Newly diagnosed patients with breast cancer presenting with operable breast tumor prior to initiation of of neoadjuvant chemotherapy (choice of chemotherapy will be the the treating physician's discretion)"
                        },
                        {
                            "ArmGroupLabel": "Healthy volunteers",
                            "ArmGroupDescription": "Adult women without a cancer diagnosis."
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "To characterize protein surface markers and RNA profiles in tumor derived exosomes from breast cancer patients undergoing neoadjuvant chemotherapy",
                            "PrimaryOutcomeDescription": "Compare tumor derived exosomes at baseline, monthly during chemotherapy, at the completion of chemotherapy treatment, and after surgery to determine residual cancer burden. Tumor derived exosome expression will be correlated with both clinical and pathologic response.",
                            "PrimaryOutcomeTimeFrame": "up to 2 years from start of study"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nWomen with biopsy proven invasive carcinoma of the breast\nWomen with locally advanced breast cancer and breast tumors measuring >/= 2cm who are deemed candidates for preoperative chemotherapy\nAge >/= 18 years old\nExpected survival >/= 6 months\nEastern Cooperative Oncology Group performance status of 0, 1, or 2 at initiation of study\nInitial required laboratory values:\n\nAbsolute neutrophil count >/= 1.5 x 10(9)/L Platelet count >/= 100,000 x 10(9)/L Creatinine clearance >/= 50mL/min (calculated by Cockcroft-Gault method) Liver function tests (AST, ALT, total bilirubin) </= 2.5 x ULN Urine or serum HCG negative (if female of childbearing potential)\n\nWomen may be enrolled on ongoing therapeutic preoperative chemotherapy trials\n\nExclusion Criteria:\n\nNo prior chemotherapy for breast cancer\nNo limitations for prior radiation therapy\nNo active, serious infection or medical or psychiatric illness likely to interfere with participation in this trial\nNon-pregnant and non-nursing patients only. Patients of reproductive potential must agree to use an effective means of birth control\nNo prior liver transplant or bone marrow transplant",
                "HealthyVolunteers": "Accepts Healthy Volunteers",
                "Gender": "Female",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                },
                "StudyPopulation": "Newly diagnosed breast cancer patients prior to neoadjuvant chemotherapy treatment and healthy volunteers",
                "SamplingMethod": "Non-Probability Sample"
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Rachel Raab, MD",
                            "OverallOfficialAffiliation": "Brody School of Medicine at ECU",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Leo W. Jenkins Cancer Center",
                            "LocationCity": "Greenville",
                            "LocationState": "North Carolina",
                            "LocationZip": "27834",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Neoplasms",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            }
        }
    }
}